Regenica is developing a dynamic pipeline of next-generation medical countermeasures to biochemical terrorism.

Regenica is focused exclusively on high-quality candidates that display powerful clinical effects and favorable safety profiles. Through ultra-efficient preclinical programs, Regenica quickly derisks candidates to optimize the likelihood of success.


Regenica combines the lean and nimble flexibility of a biotech company with the scaled regulatory efficiency of a government defense firm. This allows Regenica to provide quality therapeutics to vulnerable patient populations in record time.


Regenica’s lead compound, REG-001 is a novel small-molecule antidote protecting against a broad class of weaponized nerve agents.

Learn More


Regenica plans to develop a vector platform allowing for inoculation and protection against tier-1 select biological agents.

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from Youtube
Consent to display content from Vimeo
Google Maps
Consent to display content from Google